Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

ABSTRACT:

Context

Considerable advances have been made in the first-line treatment of metastatic renal cell carcinoma (mRCC), with immunotherapy-based combinations including immunotherapy-tyrosine kinase inhibitors (IO-TKIs) and dual immunotherapy (IO-IO) favored. A lack of head-to-head clinical trials comparing these treatments means that there is uncertainty regarding their use in clinical practice.

Objective

To compare and rank the efficacy and safety of first-line systemic treatments for mRCC with a focus on IO-based combinations.

Evidence acquisition

MEDLINE (Ovid), EMBASE, Cochrane Library, Web of Science, and abstracts of recent major scientific meetings were searched to identify the most up-to-date phase 3 randomized controlled trials (RCTs) of first-line IO-based combi

SUBMITTER: Bosma NA 

PROVIDER: S-EPMC8792068 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature